APA (7th ed.) Citation

Olivier Godeaux, Martina Kovac, Daniel Shu, Katrijn Grupping, Laura Campora, Martine Douha, . . . Himal Lal. (2017). Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ≥ 50 years of age with a prior history of herpes zoster: A phase III, non-randomized, open-label clinical trial. Taylor & Francis Group.

Chicago Style (17th ed.) Citation

Olivier Godeaux, Martina Kovac, Daniel Shu, Katrijn Grupping, Laura Campora, Martine Douha, Thomas C. Heineman, and Himal Lal. Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in Adults ≥ 50 years of Age with a Prior History of Herpes Zoster: A Phase III, Non-randomized, Open-label Clinical Trial. Taylor & Francis Group, 2017.

MLA (9th ed.) Citation

Olivier Godeaux, et al. Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in Adults ≥ 50 years of Age with a Prior History of Herpes Zoster: A Phase III, Non-randomized, Open-label Clinical Trial. Taylor & Francis Group, 2017.